Articles

Article

Review Article

Exp Neurobiol 2016; 25(6): 277-295

Published online December 31, 2016

https://doi.org/10.5607/en.2016.25.6.277

© The Korean Society for Brain and Neural Sciences

Molecular Neuroimaging in Posttraumatic Stress Disorder

Jooyeon Jamie Im1,2, Eun Namgung1,3, Yejee Choi1,3, Jung Yoon Kim1,3, Sandy Jeong Rhie1,4 and Sujung Yoon1,3*

1Ewha Brain Institute, Ewha Womans University, Seoul 03760, 2Interdisciplinary Program in Neuroscience, College of Natural Sciences, Seoul National University, Seoul 08826, 3Department of Brain and Cognitive Sciences, Ewha Womans University, Seoul 03760, 4College of Pharmacy and Division of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea

Correspondence to: *To whom correspondence should be addressed.
TEL: 82-2-3277-2478, FAX: 82-2-3277-6562
e-mail: sujungjyoon@ewha.ac.kr

Received: October 11, 2016; Revised: November 11, 2016; Accepted: November 14, 2016

Over the past decade, an increasing number of neuroimaging studies have provided insight into the neurobiological mechanisms of posttraumatic stress disorder (PSTD). In particular, molecular neuroimaging techniques have been employed in examining metabolic and neurochemical processes in PTSD. This article reviews molecular neuroimaging studies in PTSD and focuses on findings using three imaging modalities including positron emission tomography (PET), single photon emission computed tomography (SPECT), and magnetic resonance spectroscopy (MRS). Although there were some inconsistences in the findings, patients with PTSD showed altered cerebral metabolism and perfusion, receptor bindings, and metabolite profiles in the limbic regions, medial prefrontal cortex, and temporal cortex. Studies that have investigated brain correlates of treatment response are also reviewed. Lastly, the limitations of the molecular neuroimaging studies and potential future research directions are discussed.

Keywords: Posttraumatic stress disorder (PTSD), Molecular neuroimaging, Positron emission tomography (PET), Single photon emission computed tomography (SPECT), Magnetic resonance spectroscopy (MRS)

Posttraumatic stress disorder (PTSD) is a debilitating psychiatric disorder that is characterized by intrusion symptoms, avoidance, negative alterations in cognitions and mood, and heightened arousal and reactivity following a traumatic event [1]. A growing number of structural and functional neuroimaging studies have been conducted to investigate the pathophysiology of PTSD over the past decade. Advances in molecular imaging have allowed non-invasive methods to visualize and measure biochemical processes in human brain in vivo. Moreover, various molecular imaging modalities have been applied to elucidate molecular and neurochemical mechanisms of PTSD.

The purpose of this article is to critically review molecular neuroimaging of PTSD in humans. The term molecular neuroimaging refers to the use of imaging methods to quantitatively measure and visualize biological processes at the molecular and cellular levels in the living brain [2]. The present review focuses on three imaging modalities including positron emission tomography (PET), single photon emission computed tomography (SPECT), and proton (1H) magnetic resonance spectroscopy (MRS). The review is divided into three main sections based on the imaging modality and further divided into subsections according to the molecular targets including cerebral perfusion, metabolism, neuroreceptors, and metabolites, as well as the types of experimental interventions or paradigms that were employed.

PET is a commonly used molecular imaging technique which generates three-dimensional functional maps of neural activity such as regional cerebral metabolism or blood flow. It acquires signals during registrations of two photons at 180-degree angles and visualizes concentrations and positions of the radiotracers in certain brain areas [3]. It has advantages of relatively evident signal changes, selectivity and availability of various tracers, and heightened sensitivity compared to other functional neuroimaging modalities. For instance, PET allows pronounced signal changes (10%) in the brain, whereas 1~2% of signal changes are detected using functional magnetic resonance imaging (fMRI). However, PET has some disadvantages such as low temporal resolution compared to fMRI [4]. All PET studies reviewed in this article are presented in Table 1.

Resting state paradigms

PET studies that employed resting state paradigms are the most straightforward methods to investigate baseline cerebral metabolism and neurobiological underpinnings of PTSD. Use of a tracer called [18F]fluorodeoxyglucose (FDG) in PET studies has allowed measurement of relative glucose uptake in certain brain regions as an indirect measure of neural activity.

Two previous PET studies of PTSD have assessed regional cerebral metabolic rate for glucose (rCMRglu) at resting state. One study using FDG revealed greater rCMRglu in the temporal, occipital, and fusiform cortices, as well as cerebellum and lower rCMRglu in the insula, cingulate gyri, and hippocampus [5]. A twin study using FDG PET reported that increased metabolic rate may be a predisposing factor for PTSD development after trauma exposure rather than acquired characteristics. Veterans with PTSD and their co-twins showed augmented resting metabolic activity in the dorsal anterior cingulate cortex (dACC) and mid-cingulate cortex (MCC) as compared with non-PTSD veterans and their co-twins. In addition, resting metabolic rate of the dACC/MCC in those unexposed to combat was associated with PTSD symptom severity of their respective combat – exposed twin pairs, suggesting its genetic predisposition to pathogenesis [6].

Symptom provocation paradigms

Symptom provocation is the most widely used paradigm in PET studies to trigger symptomatic states and elicit activities in brain regions associated with symptom manifestation. Neural activities in response to symptom provocation are compared between PTSD patients and healthy controls in order to investigate the neurobiological substrates underlying PTSD pathophysiology. Several paradigms that target fear response mechanisms, in which the amygdala is mainly involved, have been commonly used.

Glucose metabolic changes in response to administration of yohimbine, an α2-antagonist which stimulates brain adrenaline release and induces anxiety symptoms, were measured in a FDG PET study. After yohimbine administration, Vietnam veterans with PTSD exhibited anxiety symptoms and showed diminished metabolic rates in the orbitofrontal cortex (OFC), parietal cortex, and temporal cortex including the hippocampus. In contrast, healthy controls showed increased metabolic rates in the prefrontal cortex including the OFC without development of any anxiety symptoms after the administration [7]. These findings suggest that development of anxiety symptoms is related to lower metabolic rate in the higher cognitive regions including the OFC, parietal cortex, and hippocampus.

Symptom provocation paradigms

Sensory stimuli

Several PET studies of PTSD have applied trauma-related sensory stimuli (sounds, pictures, and smells) to elicit activities in brain regions related to clinical presentation of PTSD. Vietnam veterans with PTSD, who were presented with combat sounds and pictures, showed elevated regional cerebral blood flow (rCBF) in the precentral and inferior parietal cortex, posterior cingulate cortex, and lingual gyrus, all of which are involved in processing of memory, emotion, and visual information, and lower rCBF in the medial prefrontal cortex (mPFC) including the anterior cingulate cortex (ACC), compared to those without PTSD [8]. A [15O]CO2 PET study revealed relatively increased rCBF in the ventral anterior cingulate gyrus and right amygdala in the Vietnam veterans with PTSD during exposure to combat-related visual images compared to neutral images [9]. These activation patterns may underlie re-experiencing symptoms, involving mental imagery of traumatic experiences. Increased rCBF in the right sensorimotor cortex and right amygdala was also found during traumatic sound vs. neutral sound presentation in veterans with PTSD [10]. Furthermore, veterans with PTSD, who were exposed to diesel smell reminiscent of traumatic experiences, demonstrated enhanced rCBF in the prefronto-limbic regions including the amygdala, insula, and mPFC, particularly the ACC and diminished rCBF in the lateral prefrontal cortex relative to non-PTSD veterans, suggestive of alterations in memory and olfactory processing related to PTSD [11].

Script-driven imagery

Script-driven imagery, in which participants listened to either their trauma-related-autobiographical scripts or neutral scripts in the scanner, has been frequently used as a traumatic reminder in PET studies of PTSD.

Two PET studies have examined rCBF differences among sexually abused PTSD women, sexually abused non-PTSD women, and healthy women in response to traumatic vs. neutral scripts [12,13]. Bremner et al. revealed that the PTSD group had significantly reduced rCBF in the mPFC particularly the ACC, hippocampus, and visual association cortex, and increased perfusion in the motor and posterior cingulate cortices relative to the trauma-exposed non-PTSD group [12]. In a PET study using [15O]CO2, both trauma-exposed groups with and without PTSD showed elevated rCBF in the anterior paralimbic regions in response to traumatic vs. neutral conditions. However, the PTSD group relative to non-PTSD group demonstrated reduced perfusion in the anterior cingulate, left inferior frontal, and parahippocampal gyri, and greater perfusion increases in the OFC and anterior temporal pole [13]. These findings implicate that the deactivation of the cognitive areas such as the frontal cortex and hippocampus, resulting in dysfunctional emotion control, is a biological underpinning responsible for PTSD pathophysiology. This interpretation could be further supported by a PET study using [15O]H2O [14]. While veterans with and without PTSD as well as healthy noncombat individuals all exhibited mPFC deactivation, veterans with PTSD showed greater deactivation of the rostral ACC relative to the comparison groups.

In line with these findings, increased rCBF in the amygdala and diminished perfusion in the medial frontal gyrus were reported in combat veterans with PTSD who were exposed to traumatic script vs. neutral script [15]. Consistently, the PTSD group exhibited increased rCBF in the right limbic and paralimbic regions, as well as the visual cortex. Alterations in these brain regions were respectively associated with symptoms of emotional distress and re-experiencing during exposure to traumatic script vs. neutral script. Blood flow of the left inferior frontal and middle temporal cortices was relatively reduced in the PTSD group [16]. In another PET study using script-driven imagery, flashback intensity of PTSD patients was positively associated with rCBF in the brain areas involved in visuospatial cue-processing, memory, and motor control including the brain stem, bilateral insula, left hippocampal and parahippocampal, lingual, somatosensory, and cerebellar areas and negatively with rCBF in the bilateral dorsolateral prefrontal cortex (DLPFC), right fusiform gyrus, and right medial temporal cortex [17]. This inverse correlation between flashback intensity and rCBF in the DLPFC suggests dysfunctional activity of the DLPFC in PTSD patients. Interestingly, a longitudinal neuroimaging study on recovering PTSD patients found that as patients recover from PTSD, they showed greater DLPFC thickness relative to controls and the thickness eventually normalized during the recovery period [18].

Fear conditioning

Bremner et al. investigated the neural correlates during fear conditioning, fear extinction, and habituation in sexual abuse-related PTSD patients in a PET study using [15O]H2O [19]. PTSD patients showed greater rCBF in the left amygdala during fear acquisition and decreased ACC activation during extinction, relative to healthy controls. The amygdala and ACC have been suggested for their respective roles in acquisition and extinction of fear responses related to PTSD. More specifically, in PTSD subjects, fear acquisition was associated with increased activation in the bilateral superior temporal gyrus, bilateral inferior frontal gyrus, and posterior cingulate and reduced activation in the bilateral inferior frontal gyrus, bilateral superior temporal gyrus, posterior cingulate, and cerebellum. Within the PTSD group, fear extinction was related with dysfunction in the mPFC (ACC, subcallosal gyrus, OFC) and visual association cortex. Importantly, decreased perfusion in the mPFC during fear extinction was associated with heightened anxiety within the PTSD group.

These findings are consistent with the neurobiological model of PTSD implying the key role of the mPFC dysregulation over the hyperactive amygdala during acute threat in the pathophysiology of PTSD. A negative correlation found between elevated amygdalar blood flow during fear acquisition and decreased rCBF in the mPFC during fear extinction further supports this model of hyperactive amygdala and hypoactive mPFC in PTSD.

Functional connectivity

Functional connectivity analysis examines efficiency of functional coupling among brain regions, as indicated by balanced activation patterns within the brain network. PTSD literature has suggested alterations in the brain network related to higher cognitive and emotional processing. A functional connectivity analysis of PET study using [15O]H2O demonstrated that civilian trauma-related PTSD patients showed alterations in the emotional control network during traumatic vs. neutral scripts relative to the trauma-exposed non-PTSD individuals. The altered functional connectivity pattern was characterized by predominant influences of the amygdala over brain regions associated with higher-order and autonomic processing of visual memory (ACC, visual cortex, and subcallosal gyrus). Memory retrieval networks showed no differences in their connectivity patterns between PTSD and non-PTSD groups [20].

Cognitive tasks

Participating in cognitive tasks elicits predicted responses in brain regions associated with memory and emotional processing. Several PET studies have investigated the neural correlates of dysfunctional memory and emotional regulation in PTSD, using cognitive tasks that often include traumatic reminders. Findings of decreased activation in the mPFC have been replicated in PTSD patients during cognitive tasks. However, the hippocampus showed inconsistent activation patterns depending on whether the tasks involve emotional words related to trauma or not.

Non-emotional cognitive tasks

Semple and colleagues examined rCBF pattern during auditory continuous performance tasks (ACPT) in three PET studies [21,22,23]. The earlier PET studies using H2O15 reported that war veterans with PTSD during the ACPT task showed relatively higher blood flow in the OFC and lower rCBF in the hippocampus and parietal cortex [21,22].

These findings were not entirely replicated by a more recent PET study using [15O] butanol. War veterans with PTSD, while performing ACPT task, had relatively elevated rCBF in the right amygdala, left parahippocampal gyrus, and occipital cortex and reduced rCBF in the frontal cortex, including the ACC, relative to the comparison group [23]. Similarly, firefighters with PTSD compared to those without PTSD showed higher rCBF in the left amygdala and bilateral hippocampus during explicit retrieval of non-emotional words, in a PET study using a word-stem completion task. Within the PTSD group, a positive association was found between PTSD symptom severity and rCBF in the hippocampus and parahippocampus [24].

These findings of the hyperactive hippocampus during cognitive tasks were not replicated in a PET (H2O15) study using the hippocampal-based verbal declarative memory task (paragraph-encoding task) [25]. PTSD patients with childhood sexual abuse history, relative to the trauma-exposed non-PTSD group, demonstrated the left hippocampal deactivation, along with lower rCBF in the OFC and cerebellum.

Shaw et al., using an n-back working memory task, reported alterations in memory network connectivity in PTSD patients, specifically characterized by hyperactivation in the left precentral gyrus and bilateral inferior parietal lobes and hypoactivation in the fronto-temporal regions including the bilateral middle frontal gyri, inferior medial frontal lobe, and right inferior temporal gyrus [26].

Emotional-cognitive tasks

PET (H2O15) studies have examined the neural responses of female PTSD patients with sexual abuse history during the cognitive tasks including the traumatic reminders (words such as ‘rape’ or ‘mutilate’). Dysfunction in brain regions related to memory and emotion has been suggested as PTSD-specific neural substrates [27,28].

Specifically, the PTSD group, relative to the non-PTSD comparison group, had lower rCBF in the mPFC (ACC and OFC), left hippocampus, and inferior temporal gyrus/fusiform gyrus and increased perfusion in the left middle frontal gyrus, visual association cortex, left inferior parietal cortex, and posterior cingulate cortex during the performance of an emotional world retrieval task [27].

Another [15O]H2O PET study using the emotional Stroop task further adds evidence in support of the ACC dysfunction as neural correlates underlying PTSD pathophysiology. Women with PTSD showed decreased rCBF in the ACC, while performing the emotional Stroop task (naming the color of the word, ‘rape’), but not during the classical Stroop task [28].

Opioids

A PET study using [11C]carfentanil as a tracer has provided neurobiological evidence for the role of opioid system in the development of PTSD [29]. The combat-related PTSD patients showed lower micro-opioid receptor binding potential in the ACC, implying dysfunctional stress coping. In contrast, the combat-exposed non-PTSD individuals showed decreases in micro-opioid receptor-binding potential of the amygdala and increases in that of the OFC. Both veterans with and without PTSD relative to healthy controls showed greater binding potential in the OFC and lower binding potential in the dorsal frontal and insular cortex, nucleus accumbens, and amygdala. In addition, lower in vivo kappa-opioid receptor availability in the amygdala-ACC-ventral striatal neural circuit of trauma-exposed individuals was associated with their trauma-related loss symptoms [30]. Veterans with PTSD showed heightened concentrations of cannabinoid type 1 (CB1) receptor in the ACC, OFC, and amygdala relative to healthy controls, leading to upregulation of glucorticoid system, increased norepinephrine projections to the amygdala, and hyperconsolidation of traumatic memories. Atypical signaling mediated by elevated brain CB1 receptor along with lower anandamide and cortisol levels of PTSD veterans could be implicated as a promising biomarker related to PTSD etiology [31].

Serotonin

A PET study with [11C]WAY-100635 reported higher serotonin-1A (5-HT1A) binding i the forebrain and brainstem of patients with PTSD relative to healthy controls, which could be regarded as a potential brain biomarker for stress exposure. PTSD patients with and without comorbid major depression showed higher in vivo 5-HT1A binding in the amygdala and brain stem raphe nuclei, leading to less release of serotonin and then mood imbalance [32]. However, this was challenged by non-significant findings of 5-HT1A receptor concentrations related to PTSD [33].

In a [11C]P943 PET study, PTSD-related anxious arousal symptoms could potentially be explained by increased serotonin-1A (5-HT1B) heteroreceptors in the pallidum and hippocampus, which may influence the glutamatergic activity. Decreased 5-HT1B receptors in the hippocampus were associated with behavioral inhibition and numbing symptoms in PTSD patients partly due to the imbalance between excitatory and inhibitory neurotransmission and modulation of gamma aminobutyric acidergic outputs [34]. Furthermore, a lower degree of overlapping expression of both serotonin transporters and neurokinin-1 receptors in the insula, putamen, thalamus, and lateral orbitofrontal gyrus of PTSD patients was correlated with greater PTSD symptom severity in a PET study using multi-tracers including [11C]-3-amino-4 and [11C]GR205171 [35].

Others

Veterans with chronic PTSD relatively showed a reduction in norepinephrine transporter availability in the locus coeruleus, which was positively associated with the severity of hypervigilance symptoms [36]. Another PET study reported lower [11C]flumazenil binding in the hippocampus and thalamus in combat veterans with PTSD, indicating diminished function of benzodiazepine/gamma aminobutyric acid-A (GABAA) receptor related to PTSD pathology [37].

SPECT is a molecular imaging modality which uses tracers labeled with gamma-emitting radioactive isotopes [38]. Although SPECT offers poorer spatial resolution relative to PET, it is widely used due to its comparatively less sophisticated and inexpensive methodology [39]. Accordingly, a number of studies have employed SPECT in investigating molecular pathophysiology of PTSD. Using SPECT, cerebral perfusion and neuroreceptor density have been measured as the metabolic activities and neurochemistry related to PTSD. Moreover, SPECT has been used for evaluation of the neural mechanisms underlying the responses to pharmacological and psychotherapy treatments. All SPECT studies included in this review are presented in Table 2.

Resting state paradigms

Most SPECT studies on PTSD have examined alterations in rCBF, which are measured by the uptake of radioactive tracer in certain brain areas and often interpreted as an indirect measure of brain activity. Using resting state paradigms, several studies have used SPECT to investigate regional cerebral perfusion in patients with PTSD.

In a SPECT study using technetium-99m hexamethylpropylenamine oxime (Tc-99m HMPAO), PTSD patients showed an increase in rCBF in the anterior and posterior cingulate cortices, right temporal and parietal cortices, right caudate/putamen region, and left orbital and hippocampal regions compared with healthy controls during resting conditions [40]. When the analysis was restricted to medication-free PTSD patients compared with controls, an increase in rCBF was found only in the ACC, caudate/putamen regions, and right orbital cortex.

Using a different radioactive tracer of technetium-99m ethyl cysteinate dimer (Tc-99m ECD), Chung et al. replicated some of the results of Sachinvala [40] such as increased rCBF in the ACC and hippocampus related to PTSD [41]. Additionally, this study reported an increase of cerebral perfusion in the parahippocampal gyrus, isthmus of cingulate gyrus, and rhinencephalon and a decrease in the left frontal precentral, inferior temporal, and parietal angular gyri. Overall, the results from both studies suggest the involvement of the limbic areas in the pathophysiology of PTSD. Moreover, alterations of cerebral blood perfusion in the limbic regions in PTSD patients are consistent with the previous findings [9,11,16,23,42].

Elevated rCBF was found in the cerebellum of PTSD patients compared with both trauma-exposed and unexposed healthy controls in a SPECT study using Tc-99 HMPAO [43]. Moreover, PTSD patients exhibited an increase in cerebral perfusion in the left inferior lateral temporal lobe and left supramarginal gyrus to the postcentral gyrus compared with trauma-exposed controls, as well as an increase in the right precentral, superior temporal, inferior temporal, and fusiform gyri compared with trauma-unexposed controls. In another study using Tc-99 HMPAO, an increased level of cerebral perfusion was found in the right superior parietal lobe and a decrease in the right thalamus compared to healthy controls [44]. The authors suggest that the decreased thalamic rCBF may be a coping strategy to reduce re-experiencing symptoms by eluding the process of information that are related to the traumatic event. The role of the thalamus in sensory gating related to the traumatic event has been further supported by a recent study examining dynamic changes in amygdalar connectivity to the thalamus during recovery from PTSD [45].

Interestingly, two SPECT studies have reported interhemispheric asymmetry of cerebral perfusion in PTSD patients. Specifically, PTSD patients showed higher cerebral blood flow in the left hemisphere than in the right, most notably in the temporoparietal region [46] and in the projection area of the ventral basal ganglia [47].

Symptom provocation paradigms

In symptom provocation paradigms, individuals are exposed to certain stimuli to elicit trauma-related symptoms. A few SPECT studies of PTSD have been performed using auditory stimulus such as combat sounds or personalized trauma scripts. In veterans with combat related trauma, an elevated level of rCBF was observed in the mPFC, left amygdala, and left nucleus accumbens during exposure to combat sounds [42,48]. One of the veterans from the study experienced a full-blown flashback following exposure to combat sounds. This case was not included in the final analysis and was reported separately in a different study [49]. During his flashback, the veteran showed greater uptake in subcortical regions compared with cortical regions, particularly in the thalamus, suggesting corticothalamic dysfunction as possibly playing a role in flashbacks. In another SPECT study with Tc-99 HMPAO, Lindauer et al. used script driven imagery to examine rCBF in police officers with PTSD in comparison to trauma-exposed controls [50]. In the traumatic versus neutral conditions, rCBF increase was found in the right cuneus and decrease in the medial frontal gyrus.

Two of these SPECT studies using symptom provocation paradigms reported inconsistent findings on the mPFC [48,50]. A large body of literature on PTSD suggests that the mPFC plays a critical role in pathogenesis of PTSD. Dysfunctions in the mPFC may lead to failed suppression of fear responses. While some PET and SPECT studies have confirmed this view [8,12,13,14,27,50], other studies have found no significant findings [10,17,43,46] and some studies even found hyperactivation [9,16,40,48].

Pharmacotherapy

The most commonly studied pharmacological treatment for PTSD involves SSRI medications [52]. Seedat et al. conducted a SPECT Tc-99 HMPAO study in patients who were treated with SSRI, citalopram, for 8 weeks [53]. SPECT data were obtained twice before and after the treatment to examine the effects of SSRI on rCBF. The study reported that PTSD patients who were treated with SSRI showed significant deactivation in the left medial temporal cortex. The authors suggest that reduced activity in the medial temporal cortex may be due to SSRI-induced effects and then improvement of PTSD symptoms. This finding of normalization of the temporo-limbic dysregulation with treatment in PTSD patients is consistent with some of the previous studies [7,13,16,46].

Psychotherapy

The effectiveness of psychotherapies including CBT and EMDR in treating patients with PTSD has been validated in a number of studies [51]. A SPECT study using Tc-99m ECD have investigated the effects of exposure-based and cognitive restructuring therapy on the brain in individuals who have subthreshold PTSD compared with those without treatment [54]. In the post-treatment scan using personalized script driven imagery, increased activity was found in the left prefrontal cortex, left hippocampus, thalamus, and parietal lobes during memory retrieval. The authors suggest that increased rCBF in these areas may reflect better inhibition of the amygdala, better processing of trauma-related spatial and temporal information, and more efficient integrative functions.

In another SPECT study using script driven imagery, PTSD patients were observed after 16 weeks of brief eclectic psychotherapy compared to those on the waiting list and trauma-exposed controls [55]. Before psychotherapy, PTSD patients showed greater rCBF in the right insula and right superior/middle frontal gyrus compared with controls. After psychotherapy, patients who received treatment showed lowered rCBF in the right middle frontal gyrus compared with patients who were put on the waiting list. Reduced activation in the medial frontal gyrus following the treatment has not been in line with the existing literature. The authors explain that possible reasons for this discrepancy include differences in patient populations, paradigms, and study design.

Three SPECT studies were performed to investigate the effects of EMDR in PTSD patients. Levin et al. acquired scans before and after 3 sessions of EMDR treatment using script driven imagery paradigm in a single patient [56]. In the post-treatment scan compared to pre-treatment scan, increased activation was observed in the anterior cingulate gyrus and left frontal lobe during retrieval of the traumatic memory. The authors reported that these changes were consistent in 4 of 6 patients from their ongoing study. Using technetium-99m exametazime, police officers with PTSD were scanned before and after EMDR treatment [57]. During scanning, the patients performed a standardized concentration task to simulate their daily functioning. In post-treatment scan, increased rCBF was found in the left frontal lobe, most notably in the inferior frontal gyrus, and decreased rCBF was observed in the right thalamus, precentral gyrus of the right frontal lobe, postcentral gyrus of the left parietal lobe, and occipital lobe.

In another SPECT Tc-99 HMPAO study examining the effects of EMDR treatment, baseline examinations revealed greater rCBF in the OFC, temporal pole, and medial temporal cortex, notably in the uncus, during script driven imagery paradigm [58]. After the treatment, increased rCBF remained significant in the OFC and temporal pole which extended to the lateral temporal cortex and to the hypothalamus. All three studies that investigated the effects of EMDR reported an increase in rCBF in the left frontal cortex. The authors attributed these discrepancies among the studies to differences in sample size, trauma type, or inclusion of a control group.

Benzodiazepine

Animals that have been exposed to excessive stress showed a decrease in benzodiazepine receptor binding in the frontal cortex [62]. Moreover, given the clinical efficacy of benzodiazepine-type medications in treating anxiety symptoms in PTSD, decreased benzodiazepine receptor binding in the frontal cortex may play a role in the maintenance of PTSD symptoms. Using a SPECT imaging technique with [123I]iomazenil, the binding potential of central benzodiazepine receptors were examined [59]. The authors found a lower distribution volume of benzodiazepine receptors in the prefrontal cortex (Brodmann's area 9) among 13 Vietnam War veterans with PTSD compared with healthy controls. However, another study using the same imaging modality with [123I] iomazenil did not confirm this finding in 19 Gulf War veterans with PTSD [60]. The authors from the latter study explained that the differences in severity of symptoms, duration of illness, and choice of control group may account for the inconsistent findings.

Dopamine

A growing number of evidence has suggested that hyperdopaminergic activity may underlie the molecular mechanisms involved in the development and maintenance of PTSD, especially with regard to arousal symptoms [63,64,65,66]. In a SPECT study with technetium-99m TRODAT-1, the dopamine transporter binding potential was measured in the striatum as the region of interest in patients with PTSD [61]. The results of the study reported that PTSD patients showed greater dopamine transporter density in the bilateral striatum compared to trauma-exposed individuals without PTSD.

Magnetic resonance spectroscopy (MRS) is a non-invasive brain imaging method for measuring the concentration of neurochemical metabolites in the living brain. While MRS can be used to measure a variety of nuclei and isotopes such as proton (1H), carbon (13C), fluorine (19F), phosphorus (31P), and lithium (7Li), 1H- and 31P-MRS are most commonly used because they are abundant in brain tissue and allow analysis of a variety of metabolites [67]. This review focuses on studies using 1H-MRS since there have not been studies using 31P-MRS in PTSD patients. The major neurochemical metabolites that can be measured by 1H-MRS include N-acetylaspartate (NAA), choline-containing compounds (Cho), creatine and phosphocreatine (Cr), gamma aminobutyric acid (GABA), and glutamate-glutamine complex (Glx). Each metabolite shows a distinct peak in the 1H-MRS [68]. In the normal brain, the major peaks are from N-acetyl groups of NAA (2.1 ppm), Cr (3.02 ppm), and Cho (3.22 ppm) and minor peaks include Glx (2.1~2.4 ppm) and myoinositol (Ino) (3.55 ppm). Therefore, alterations in these major peaks may implicate changes in neurochemical metabolites that are associated with psychiatric disorders. All MRS studies reviewed in this article are presented in Table 3.

N-acetylaspartate

NAA is an excitatory neurotransmitter which contributes to neuronal integrity [75]. NAA is also considered to be an indicator of neuronal density [76]. A number of studies have found that NAA reductions are associated with brain pathologies [77,78,79,80] or psychiatric disorders [81,82,83]. Specifically, NAA reductions have been observed in patients with PTSD relative to healthy controls [75,84,85,86].

Reduced NAA levels [84,85,86,87] and NAA/Cr ratios [75,88,89,90,91] in PTSD patients have been detected in the hippocampus. This may be partly due to PTSD-related hippocampal damage. In line with these findings, NAA/Cr ratio reductions were also found in the medial temporal lobe structures of patients with PTSD [76]. Moreover, reductions of NAA levels or NAA/Cr ratios in the hippocampus were related to PTSD symptom severity. Specifically, the NAA/Cr ratio was negatively correlated with the total scores of the Clinician-Administered PTSD Scale (CAPS), as well as the symptom cluster scores (re-experiencing, avoidance, and hyperarousal) of the CAPS [92]. Likewise, it has been reported that NAA levels of the bilateral hippocampus were negatively correlated with re-experiencing symptom severity in PTSD patients [86]. In contrast, another study showed that the NAA/Cr ratio in the medial temporal lobe, where the hippocampus is located, was positively correlated with re-experiencing symptom severity in patients with PTSD [93]. However, this finding was not replicated in a different study on similar participants [94].

The ACC has received attention in PTSD research, considering its role in processing of anxiety and extinction of conditioned fear responses. Although there are inconsistent findings [95], most previous 1H-MRS studies have reported that the NAA/Cr ratio in the ACC was lower in PTSD patients than healthy controls [75,86,89,91,96].

Choline

Cho signal has been known as an indicator of cellular density [68]. A few 1H-MRS studies have been performed to investigate alterations in Cho concentrations related to PTSD. The Cho/Cr ratio was increased in the bilateral hippocampus [89], ACC [95], and cingulate gyrus [91] of PTSD patients as compared with healthy controls. In addition, higher Cho/Cr ratio was associated with more severe PTSD symptoms measured using the CAPS [92]. However, Bo et al. did not find significant differences in Cho/Cr ratio or Cho levels between PTSD patients and healthy controls [87].

Gamma-aminobutyric acid and Glutamate-glutamine complex

As GABA is an inhibitory neurotransmitter and modulates neuronal excitability [37], alterations in GABA levels have been implicated in the pathophysiology of anxiety disorders, including PTSD [97]. Partly due to relatively low concentration of GABA in the human brain and its overlapping resonance with other metabolites, specific acquisition methodology with increased field strength of MRI scanners [98] as well as special editing techniques such as MEGA-PRESS [99] or MEGA-sLASER [100] may be required to accurately measure GABA levels. Therefore, only a few studies have been performed to examine GABA levels in patients with PTSD so far. A higher GABA level was found in the DLPFC and ACC of patients with PTSD relative to healthy controls [101]. The authors interpreted this results as enhanced inhibitory neurotransmission to reduce PTSD symptoms. In contrast, GABA levels were lowered in the insula [102], parieto-occipital cortex [96], and medial temporal cortex [96] of patients with PTSD than healthy controls. Although the number of studies was limited, a recent meta-analysis has reported no significant alterations in GABA levels related to PTSD [69].

As an excitatory neurotransmitter, Glx signal has been related to encoding of fear memory in anxiety disorders [96,103]. The level of Glx signal was higher in the medial temporal cortex of PTSD patients relative to healthy controls [96]. This may be normalized with recovery of PTSD symptoms [103]. Since only a few previous 1H-MRS studies have investigated GABA or Glx in PTSD patients, more studies are needed to reveal the role of GABA or Glx in PTSD pathophysiology.

Taken together, molecular neuroimaging research reviewed in this article revealed alterations of cerebral metabolism and perfusion, ligand bindings, and metabolite concentrations in the limbic regions, mPFC, and temporal cortex in patients with PTSD. Although it is generally agreed that increased brain activity in the limbic regions and decreased activity in the mPFC are involved in the pathophysiology of PTSD, several inconsistent results have been reported due to the fact that the molecular mechanisms of PTSD are complex and multifaceted. Moreover, differences in sample size, trauma type, severity and/or duration of illness, medication use, comorbid conditions, inclusion of control group, and experimental paradigms have been considered as possible reasons for the discrepancies in the findings. Alternatively, future studies may consider a larger longitudinal study with various trauma types including both trauma-exposed and non-exposed control groups. Furthermore, a multimodal molecular neuroimaging study could potentially integrate the strengths while overcoming the limitations of individual modalities, offering a comprehensive view of neurobiological mechanisms underlying PTSD.

Table. 1. PET studies in patients with PTSD
PET studies of regional cerebral metabolism
StudyConditionPTSDControlIncreased/decreasedBrain regions
Mollina et al. (2007) [5]Resting156 (non-PTSD)↑rCMRglu↓rCMRgluTemporal, occipital, fusiform cortices, and cerebellum Insula, cingulate gyri, and hippocampus
Shin et al. (2009) [6]Resting(1) 14 (2) 19 (non-PTSD)(3) 14 (co-twin HC) (4) 19 (co-twin HC)(1), (2)>(3), (4)dACC and MCC
Bremner et al. (1997) [7]Symptom provocation1010 (HC)↓ MetabolismOFC, parietal cortex, and temporal cortex including the hippocampus
PET studies of regional cerebral blood flow
StudyConditionParadigmPTSDControlIncreased/decreasedBrain regions
Bremner et al. (1999) [8]Symptom provocationSensory stimuli1010 (non-PTSD)Posterior cingulate, precentral/inferior parietal cortex, and lingual gyrus mPFC including ACC
Shin et al. (1997) [9]Symptom provocationSensory stimuli77 (non-PTSD)Ventral ACG and right amygdala Broca's area
Pissiota et al. (2002) [10]Symptom provocationSensory stimuli17-Right sensorimotor cortex and right amygdala
Vermetten et al. (2007) [11]Symptom provocationSensory stimuli88 (non-PTSD)Amygdala, insula, mPFC, and ACC Lateral PFC
Bremner et al. (1999) [12]Symptom provocationScript-driven imagery1010 (non-PTSD)Motor and posterior cingulate cortices mPFC (particularly ACC), hippocampus, and visual association cortex
Shin et al. (1999) [13]Symptom provocationScript-driven imagery88 (non-PTSD)[All trauma exposed group (PTSD+non-PTSD)] OFC and anterior temporal poles↓ Left inferior frontal gyrus
Britton et al. (2005) [14]Symptom provocationScript-driven imagery1615 (non-PTSD) 14 (HC)rACC
Shin et al. (2004) [15]Symptom provocationScript-driven imagery1719 (non-PTSD)Amygdala Medial frontal gyrus
Rauch et al. (1996) [16]Symptom provocationScript-driven imagery8 (traumatic scripts)8 (PTSD) (neutral scripts)Right limbic and paralimbic regions and visual cortex Left inferior frontal and middle temporal cortcies
Osuch et al. (2001) [17]Symptom provocationScript-driven imagery12-Brainstem, lingual, bilateral inusla, right putamen, left hippocampal/parahippocampal, somatosensory, and cerebellar regions DLPFC, right fusiform gyrus, and right MTC
Bremner et al. (2005) [19]Symptom provocationFear conditioning811 (non-PTSD)Left amygdala ACC
Giloba et al. (2004) [20]Symptom provocationFunctional connectivity1412 (non-PTSD)Effective connectivityAmygdala on visual cortex, subcallosal gyrus, and AC
Semple et al. (1993) [21]Active taskEmotion-unrelated67 (HC) ↓Perfusion ratioOFC Left/right hippocampus
Semple et al. (1996) [22]Active taskEmotion-unrelated88 (HC)Parietal cortex
Semple et al. (2000) [23]Active taskEmotion-unrelated76 (HC)Right amygdala, left parahippocampal gyrus, and occipital cortex Frontal cortex including ACC
Shin et al. (2004) [24]Active taskEmotion-unrelated88 (non-PTSD)Left amygdala and bilateral hippocampus
Bremner et al. (2003) [25]Active taskEmotion-unrelated1012 (non-PTSD) 11 (HC)Left hippocampus, OFC, and cerebellum
Shaw et al. (2002) [26]Active taskFunctional connectivity1010 (HC)Left precentral gyrus, bilateral inferior parietal lobes Fronto-temporal regions
Bremner et al. (2003) [27]Active taskEmotion-related1011 (HC)Left middle frontal gyrus, visual association cortex, left IPC, and PCC mPFC, left hippocampus, and inferior temporal gyrus/fusiform gyrus
Bremner et al. (2004) [28]Active taskEmotion-related129 (non-PTSD)ACC
PET studies of labeled ligand
StudyNeuroreceptor/transporterPTSDControlIncreased/decreasedBrain regions
Frick et al. (2016) [35]5-HT transporters neurokinin-1 receptor1616 (HC)↓ ExpressionsInsula, putamen, thalamus, and lateral orbitofrontal gyrus
Liberzon et al. (2007) [29]Micro-opioid receptors1614 (non-PTSD) 14 (HC)↓ Binding potentialsACC and amygdala
Pietrzak et al. (2014) [30]Kappa-opioid receptors35 (30 traumaexposed, 5 HC)-↓ ReceptorsAmygdala-ACC-ventral striatal neural circuit
Neumeister et al. (2013) [31]Brain cannabinoid CB1 receptor2512 (non-PTSD) 23 (HC)↑ ReceptorsACC, amygdala, OFC
Sullivan et al. (2013) [32]5-HT(1A) receptors2049 (HC)↑ BindingsAmygdala and brainstem raphe nuclei
Bonne et al.(2005) [33]5-HT(1A) receptors1211 (HC)-Not significant
Pietrzak et al.(2013) [34]5-HT(1B) receptors49-↑ 5-HT1B heteroreceptors↓ ReceptorsPallidum and hippocampus - associated with anxious arousal symptoms Hippocampus - associated with behavioral inhibition and numbing symptoms
Pietrzak et al.(2013) [36]NET2216 (non-PTSD) 18 (HC)↓ TransportersLocus coeruleus
Geuze et al.(2008) [37]GABA(A) receptors97 (non-PTSD)↓ BindingsCortex, hippocampus and thalamus

The ↑symbol indicates an increase, and ↓a decrease..

5-HT, 5-hydroxytryptamine (serotonin); AC, anterior cingulate; ACC, anterior cingulate cortex; ACG, anterior cingulate gyrus; CATs, catecholamines; dACC, dorsal anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; GM, gray matter; HC, healthy controls; IPC, inferior parietal cortex; MCC, medial cingulate cortex; mPFC, medial prefrontal cortex; MTC, medial temporal cortex; ET, norepinephrine transporter; OFC, orbitofrontal cortex; PCC, posterior cingulate cortex; PET, positron emission tomography; PFC, prefrontal cortex; PTSD, posttraumatic disorder; rACC, rostral anterior cingulate cortex; rCMRglu, resting cerebral metabolic rate for glucose..


Table. 2. SPECT studies in patients with PTSD
SPECT studies of regional cerebral blood flow
StudyConditionPTSDControlIncreased/decreasedBrain regions
Sachinvala et al. (2000) [40]Resting178 (HC)Bilateral AC/PC regions, the right temporal and parietal regions, the right caudate/putamen region, and the left orbital and hippocampal regions Restricted to drug-free PTSD: caudate/putamen regions, anterior cingulate cortex, and the right orbital cortex
Chung et al. (2006) [41]Resting2364 (HC)Limbic regionsSuperior frontal gyrus and parietal/temporal regions
Liberzon et al. (1999) [42]Symptom provocation1414 (HC) 14 (non-PTSD)Left amygdala and left nucleus accumbens
Bonne et al. (2003) [43]Resting1111 (HC) 17 (non-PTSD)Cerebellum
Kim et al. (2007) [44]Resting1919 (HC)Right superior parietal lobeRight thalamus
Mirzaei et al. (2001) [46]Resting88 (HC)Interhemispheric asymmetryLeft > right in the temporoparietal region in PTSD group
Pavic et al. (2003) [47]Resting25-Interhemispheric asymmetryLeft > right in projection area of ventral basal ganglia in 13 of 25 participants
Zubieta et al. (1999) [48]Symptom provocation1212 (HC) 11 (non-PTSD)Medial prefrontal cortex
Liberzon et al. (1996) [49]Symptom provocation1-Subcortical regions, particularly the thalamus, during a flashback
Lindauer et al. (2004) [50]Symptom provocation1515 (non-PTSD)Right cuneusMedial frontal gyrus
SPECT studies examining treatment responses*
StudyTherapyPTSDControlIncreased/decreasedBrain regions
Seedat et al. (2004) [53]Pharmacotherapy11-Left medial temporal cortex
Peres et al. (2007) [54]Psychotherapy1611 (non-PTSD)Parietal lobes, left hippocampus, thalamus, and left prefrontal cortex
Lindauer et al. (2008) [55]Psychotherapy2015 (non-PTSD)Right middle frontal gyrus
Levin et al. (1999) [56]Psychotherapy6-Anterior cingulate gyrus and left frontal lobe in 4 of 6 patients
Lansing et al. (2005) [57]Psychotherapy6-Left inferior frontal gyrus Bilateral occipital lobe, left parietal lobe, and right precentral frontal lobe
Pagani et al. (2007) [58]Psychotherapy1527 (non-PTSD)Orbitofrontal cortex and temporal pole, extended to the lateral temporal cortex and to the hypothalamus
SPECT studies of labeled ligand
StudyNeuroreceptor/transporterPTSDControlIncreased/decreasedBrain regions
Bremner et al. (2000) [59]BZD receptor binding1313 (HC)Prefrontal cortex
Fujita et al. (2004) [60]BZD receptors1919 (HC)-No regional differences
Hoexter et al. (2012) [61]DAT density2121 (non-PTSD)Bilateral striatal DAT

The ↑symbol indicates an increase, and ↓ a decrease..

*Only post-treatment findings are included..

AC, anterior cingulate; BZD, benzodiazepine; DAT, dopamine transporter; HC, healthy controls; PC, posterior cingulate; PTSD, posttraumatic disorder; SPECT, single photon emission computed tomography..


Table. 3. <sup>1</sup>H-MRS studies in patients with PTSD
StudyMethodPTSDControlROIMain findings
N-acetylaspartate
De Bellis et al. (2000) [75]NAA/Cr ratio1111 (HC)ACC↓ in the ACC
Freeman et al. (1998) [76]NAA/Cr ratio218 (non-PTSD)TLS↓ in the right medial TLS
Schuff et al. (2001) [84]NAA1819 (HC)Hippocampus↓ about 23% in the bilateral hippocampus
Ham et al. (2007) [86]NAA2625 (HC)ACC↓ in the ACC
Negatively related with re-experience symptom scores
Hippocampus↓ in the bilateral hippocampus
Negatively related with re-experience symptom scores
Bo et al. (2006) [87]NAA1717 (HC)Hippocampus↓ in the bilateral hippocampus
Mohanakrishnan Menon et al. (2003) [88]NAA/Cr ratio147 (non-PTSD)Hippocampus↓ in the left hippocampus
Mahmutyazıcıoğlu et al. (2005) [89]NAA/Cr ratio106 (HC)ACC↓ in the ACC
Hippocampus ↓ in the bilateral hippocampus
Li et al. (2006) [90]NAA/Cr ratio1212 (non-PTSD)Hippocampus↓ in the left hippocampus
Guo et al. (2012) [91]NAA/Cr ratio5050 (HC)ACG↓ in the ACG
Hippocampus ↓ in the bilateral hippocampus
Shu et al. (2013) [92]NAA/Cr ratio1111 (HC)Hippocampus↓ in the bilateral hippocampus
Negatively related with re-experience, avoidance, and hyper-arousal symptom scores
Brown et al. (2003) [93]NAA/Cr ratio9 POWs12 POWs (non-PTSD)MTL↓ in the left MTL
Strongly correlated with re-experiencing symptom scores in PTSD group
Freeman et al. (2006) [94]NAA/Cr ratio10 POWs10 POWs (non-PTSD)HippocampusNot significant
6 (HC)
Seedat et al. (2005) [95]NAA/Cr ratio1611 (HC)ACCNot significant
Occipital GM
Meyerhoff et al. (2014) [96]NAA1718 (non-PTSD)ACC↓ in the ACC
Choline
Bo et al. (2006) [87]Cho1717 (HC)HippocampusNot significant
Mahmutyazıcıoğlu et al. (2005) [89]Cho106 (HC)ACGNot significant
Hippocampus ↑ in the bilateral hippocampus
Guo et al. (2012) [91]Cho/Cr ratio5050 (HC)ACG↑ in the ACG
Hippocampus Not significant
Shu et al. (2013) [92]Cho/Cr ratio1111 (HC)HippocampusPositively related with re-experience symptom scores
Seedat et al. (2005) [95]Cho/Cr ratio1611 (HC)ACC↑ in the ACC
StudyMethodPTSDControlROIMain findings
Gamma-aminobutyric acid and Glutamate-glutamine complex
Meyerhoff et al. (2014) [96]GABA2718 (non-PTSD)POC, MTC↓ in the POC and MTC
GluMTC↑ in the MTC
Michels et al. (2014) [101]GABA1217 (non-PTSD)ACC↑ in the ACC
DLPFC↑ in the DLPFC
Rosso et al. (2014) [102]GABA1313 (HC)Insula↓ in the insula
Dorsal ACCNot significant
Yang et al. (2015) [101]Glx/Cr ratio1021 (HC)ACCPTSD < remitted PTSD < HC
23 (remitted PTSD)

The ↑symbol indicates an increase, and ↓ a decrease..

Abbreviations: ACC, anterior cingulate cortex; ACG, anterior cingulate gyrus; Cho, choline; Cr, creatine; DLPFC, dorsolateral prefrontal cortex; GABA, gamma aminobutyric acid; Glu, glutamate; Glx, glutamate-glutamine complex; GM, gray matter; HC, healthy controls; 1H-MRS, Proton magnetic resonance spectroscopy; MTC, medial temporal cortex; MTL, medial temporal lobe; NAA, N-acetylaspartate; POC, parieto-occipital cortex; POWs, former prisoners of war; PTSD, posttraumatic disorder; ROI, region of interest; TLS, temporal lobe structure..


  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5™). 5th ed. Arlington, VA: American Psychiatric Association, 2013.
  2. Mankoff DA. A definition of molecular imaging. J Nucl Med 2007;48:Array.
  3. Francati V, Vermetten E, Bremner JD. Functional neuroimaging studies in posttraumatic stress disorder: review of current methods and findings. Depress Anxiety 2007;24:202-218.
    Pubmed
  4. Wehrl HF, Hossain M, Lankes K, Liu CC, Bezrukov I, Martirosian P, Schick F, Reischl G, Pichler BJ. Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales. Nat Med 2013;19:1184-1189.
    Pubmed
  5. Molina ME, Isoardi R, Prado MN, Bentolila S. Basal cerebral glucose distribution in long-term post-traumatic stress disorder. World J Biol Psychiatry 2010;11:493-501.
    Pubmed
  6. Shin LM, Lasko NB, Macklin ML, Karpf RD, Milad MR, Orr SP, Goetz JM, Fischman AJ, Rauch SL, Pitman RK. Resting metabolic activity in the cingulate cortex and vulnerability to posttraumatic stress disorder. Arch Gen Psychiatry 2009;66:1099-1107.
    Pubmed
  7. Bremner JD, Innis RB, Ng CK, Staib LH, Salomon RM, Bronen RA, Duncan J, Southwick SM, Krystal JH, Rich D, Zubal G, Dey H, Soufer R, Charney DS. Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. Arch Gen Psychiatry 1997;54:246-254.
    Pubmed
  8. Bremner JD, Staib LH, Kaloupek D, Southwick SM, Soufer R, Charney DS. Neural correlates of exposure to traumatic pictures and sound in Vietnam combat veterans with and without posttraumatic stress disorder: a positron emission tomography study. Biol Psychiatry 1999;45:806-816.
    Pubmed
  9. Shin LM, Kosslyn SM, McNally RJ, Alpert NM, Thompson WL, Rauch SL, Macklin ML, Pitman RK. Visual imagery and perception in posttraumatic stress disorder. A positron emission tomographic investigation. Arch Gen Psychiatry 1997;54:233-241.
    Pubmed
  10. Pissiota A, Frans O, Fernandez M, von Knorring L, Fischer H, Fredrikson M. Neurofunctional correlates of posttraumatic stress disorder: a PET symptom provocation study. Eur Arch Psychiatry Clin Neurosci 2002;252:68-75.
    Pubmed
  11. Vermetten E, Schmahl C, Southwick SM, Bremner JD. Positron tomographic emission study of olfactory induced emotional recall in veterans with and without combat-related posttraumatic stress disorder. Psychopharmacol Bull 2007;40:8-30.
    Pubmed
  12. Bremner JD, Narayan M, Staib LH, Southwick SM, McGlashan T, Charney DS. Neural correlates of memories of childhood sexual abuse in women with and without posttraumatic stress disorder. Am J Psychiatry 1999;156:1787-1795.
    Pubmed
  13. Shin LM, McNally RJ, Kosslyn SM, Thompson WL, Rauch SL, Alpert NM, Metzger LJ, Lasko NB, Orr SP, Pitman RK. Regional cerebral blood flow during script-driven imagery in childhood sexual abuse-related PTSD: a PET investigation. Am J Psychiatry 1999;156:575-584.
    Pubmed
  14. Britton JC, Phan KL, Taylor SF, Fig LM, Liberzon I. Corticolimbic blood flow in posttraumatic stress disorder during script-driven imagery. Biol Psychiatry 2005;57:832-840.
    Pubmed
  15. Shin LM, Orr SP, Carson MA, Rauch SL, Macklin ML, Lasko NB, Peters PM, Metzger LJ, Dougherty DD, Cannistraro PA, Alpert NM, Fischman AJ, Pitman RK. Regional cerebral blood flow in the amygdala and medial prefrontal cortex during traumatic imagery in male and female Vietnam veterans with PTSD. Arch Gen Psychiatry 2004;61:168-176.
    Pubmed
  16. Rauch SL, van der Kolk BA, Fisler RE, Alpert NM, Orr SP, Savage CR, Fischman AJ, Jenike MA, Pitman RK. A symptom provocation study of posttraumatic stress disorder using positron emission tomography and script-driven imagery. Arch Gen Psychiatry 1996;53:380-387.
    Pubmed
  17. Osuch EA, Benson B, Geraci M, Podell D, Herscovitch P, McCann UD, Post RM. Regional cerebral blood flow correlated with flashback intensity in patients with posttraumatic stress disorder. Biol Psychiatry 2001;50:246-253.
    Pubmed
  18. Lyoo IK, Kim JE, Yoon SJ, Hwang J, Bae S, Kim DJ. The neurobiological role of the dorsolateral prefrontal cortex in recovery from trauma. Longitudinal brain imaging study among survivors of the South Korean subway disaster. Arch Gen Psychiatry 2011;68:701-713.
    Pubmed
  19. Bremner JD, Vermetten E, Schmahl C, Vaccarino V, Vythilingam M, Afzal N, Grillon C, Charney DS. Positron emission tomographic imaging of neural correlates of a fear acquisition and extinction paradigm in women with childhood sexual-abuse-related post-traumatic stress disorder. Psychol Med 2005;35:791-806.
    Pubmed
  20. Gilboa A, Shalev AY, Laor L, Lester H, Louzoun Y, Chisin R, Bonne O. Functional connectivity of the prefrontal cortex and the amygdala in posttraumatic stress disorder. Biol Psychiatry 2004;55:263-272.
    Pubmed
  21. Semple WE, Goyer P, McCormick R, Morris E, Compton B, Muswick G, Nelson D, Donovan B, Leisure G, Berridge M, Miraldi F, Charles Schulz S. Preliminary report: brain blood flow using PET in patients with posttraumatic stress disorder and substance-abuse histories. Biol Psychiatry 1993;34:115-118.
    Pubmed
  22. Semple WE, Goyer PF, McCormick R, Compton-Toth B, Morris E, Donovan B, Muswick G, Nelson D, Garnett ML, Sharkoff J, Leisure G, Miraldi F, Schulz SC. Attention and regional cerebral blood flow in posttraumatic stress disorder patients with substance abuse histories. Psychiatry Res 1996;67:17-28.
    Pubmed
  23. Semple WE, Goyer PF, McCormick R, Donovan B, Muzic RF, Rugle L, McCutcheon K, Lewis C, Liebling D, Kowaliw S, Vapenik K, Semple MA, Flener CR, Schulz SC. Higher brain blood flow at amygdala and lower frontal cortex blood flow in PTSD patients with comorbid cocaine and alcohol abuse compared with normals. Psychiatry 2000;63:65-74.
    Pubmed
  24. Shin LM, Shin PS, Heckers S, Krangel TS, Macklin ML, Orr SP, Lasko N, Segal E, Makris N, Richert K, Levering J, Schacter DL, Alpert NM, Fischman AJ, Pitman RK, Rauch SL. Hippocampal function in posttraumatic stress disorder. Hippocampus 2004;14:292-300.
    Pubmed
  25. Bremner JD, Vythilingam M, Vermetten E, Southwick SM, McGlashan T, Nazeer A, Khan S, Vaccarino LV, Soufer R, Garg PK, Ng CK, Staib LH, Duncan JS, Charney DS. MRI and PET study of deficits in hippocampal structure and function in women with childhood sexual abuse and posttraumatic stress disorder. Am J Psychiatry 2003;160:924-932.
    Pubmed
  26. Shaw ME, Strother SC, McFarlane AC, Morris P, Anderson J, Clark CR, Egan GF. Abnormal functional connectivity in posttraumatic stress disorder. Neuroimage 2002;15:661-674.
    Pubmed
  27. Bremner JD, Vythilingam M, Vermetten E, Southwick SM, McGlashan T, Staib LH, Soufer R, Charney DS. Neural correlates of declarative memory for emotionally valenced words in women with posttraumatic stress disorder related to early childhood sexual abuse. Biol Psychiatry 2003;53:879-889.
    Pubmed
  28. Bremner JD, Vermetten E, Vythilingam M, Afzal N, Schmahl C, Elzinga B, Charney DS. Neural correlates of the classic color and emotional stroop in women with abuse-related posttraumatic stress disorder. Biol Psychiatry 2004;55:612-620.
    Pubmed
  29. Liberzon I, Taylor SF, Phan KL, Britton JC, Fig LM, Bueller JA, Koeppe RA, Zubieta JK. Altered central micro-opioid receptor binding after psychological trauma. Biol Psychiatry 2007;61:1030-1038.
    Pubmed
  30. Pietrzak RH, Naganawa M, Huang Y, Corsi-Travali S, Zheng MQ, Stein MB, Henry S, Lim K, Ropchan J, Lin SF, Carson RE, Neumeister A. Association of in vivo kappa-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology. JAMA Psychiatry 2014;71:1262-1270.
    Pubmed
  31. Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, Potenza MN, Bailey CR, Lin SF, Najafzadeh S, Ropchan J, Henry S, Corsi-Travali S, Carson RE, Huang Y. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 2013;18:1034-1040.
    Pubmed
  32. Sullivan GM, Ogden RT, Huang YY, Oquendo MA, Mann JJ, Parsey RV. Higher in vivo serotonin-1a binding in posttraumatic stress disorder: a PET study with [11C]WAY-100635. Depress Anxiety 2013;30:197-206.
    Pubmed
  33. Bonne O, Bain E, Neumeister A, Nugent AC, Vythilingam M, Carson RE, Luckenbaugh DA, Eckelman W, Herscovitch P, Drevets WC, Charney DS. No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder. Am J Psychiatry 2005;162:383-385.
    Pubmed
  34. Pietrzak RH, Henry S, Southwick SM, Krystal JH, Neumeister A. Linking in vivo brain serotonin type 1B receptor density to phenotypic heterogeneity of posttraumatic stress symptomatology. Mol Psychiatry 2013;18:399-401.
    Pubmed
  35. Frick A, Åhs F, Palmquist AM, Pissiota A, Wallenquist U, Fernandez M, Jonasson M, Appel L, Frans Ö, Lubberink M, Furmark T, von Knorring L, Fredrikson M. Overlapping expression of serotonin transporters and neurokinin-1 receptors in posttraumatic stress disorder: a multi-tracer PET study. Mol Psychiatry 2016;21:1400-1407.
    Pubmed
  36. Pietrzak RH, Gallezot JD, Ding YS, Henry S, Potenza MN, Southwick SM, Krystal JH, Carson RE, Neumeister A. Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. JAMA Psychiatry 2013;70:1199-1205.
    Pubmed
  37. Geuze E, van Berckel BN, Lammertsma AA, Boellaard R, de Kloet CS, Vermetten E, Westenberg HG. Reduced GABAA benzodiazepine receptor binding in veterans with post-traumatic stress disorder. Mol Psychiatry 2008;13:74-83.
    Pubmed
  38. Madsen MT. Recent advances in SPECT imaging. J Nucl Med 2007;48:661-673.
    Pubmed
  39. Lammertsma AA. PET/SPECT: functional imaging beyond flow. Vision Res 2001;41:1277-1281.
    Pubmed
  40. Sachinvala N, Kling A, Suffin S, Lake R, Cohen M. Increased regional cerebral perfusion by 99mTc hexamethyl propylene amine oxime single photon emission computed tomography in post-traumatic stress disorder. Mil Med 2000;165:473-479.
    Pubmed
  41. Chung YA, Kim SH, Chung SK, Chae JH, Yang DW, Sohn HS, Jeong J. Alterations in cerebral perfusion in posttraumatic stress disorder patients without re-exposure to accident-related stimuli. Clin Neurophysiol 2006;117:637-642.
    Pubmed
  42. Liberzon I, Taylor SF, Amdur R, Jung TD, Chamberlain KR, Minoshima S, Koeppe RA, Fig LM. Brain activation in PTSD in response to trauma-related stimuli. Biol Psychiatry 1999;45:817-826.
    Pubmed
  43. Bonne O, Gilboa A, Louzoun Y, Brandes D, Yona I, Lester H, Barkai G, Freedman N, Chisin R, Shalev AY. Resting regional cerebral perfusion in recent posttraumatic stress disorder. Biol Psychiatry 2003;54:1077-1086.
    Pubmed
  44. Kim SJ, Lyoo IK, Lee YS, Kim J, Sim ME, Bae SJ, Kim HJ, Lee JY, Jeong DU. Decreased cerebral blood flow of thalamus in PTSD patients as a strategy to reduce re-experience symptoms. Acta Psychiatr Scand 2007;116:145-153.
    Pubmed
  45. Yoon S, Kim JE, Hwang J, Kang I, Jeon S, Im JJ, Kim BR, Lee S, Kim GH, Rhim H, Lim SM, Lyoo IK. Recovery from posttraumatic stress requires dynamic and sequential shifts in amygdalar connectivities. Neuropsychopharmacology 2016
  46. Mirzaei S, Knoll P, Keck A, Preitler B, Gutierrez E, Umek H, Köhn H, Pecherstorfer M. Regional cerebral blood flow in patients suffering from post-traumatic stress disorder. Neuropsychobiology 2001;43:260-264.
    Pubmed
  47. Pavic L, Gregurek R, Petrović R, Petrović D, Varda R, Vukusić H, Crnković-Marković S. Alterations in brain activation in posttraumatic stress disorder patients with severe hyperarousal symptoms and impulsive aggressiveness. Eur Arch Psychiatry Clin Neurosci 2003;253:80-83.
    Pubmed
  48. Zubieta JK, Chinitz JA, Lombardi U, Fig LM, Cameron OG, Liberzon I. Medial frontal cortex involvement in PTSD symptoms: a SPECT study. J Psychiatr Res 1999;33:259-264.
    Pubmed
  49. Liberzon I, Taylor SF, Fig LM, Koeppe RA. Alteration of corticothalamic perfusion ratios during a PTSD flashback. Depress Anxiety 1996-1997;4:146-150.
  50. Lindauer RJ, Booij J, Habraken JB, Uylings HB, Olff M, Carlier IV, den Heeten GJ, van Eck-Smit BL, Gersons BP. Cerebral blood flow changes during script-driven imagery in police officers with posttraumatic stress disorder. Biol Psychiatry 2004;56:853-861.
    Pubmed
  51. Van Etten ML, Taylor S. Comparative efficacy of treatments for post-traumatic stress disorder: a meta-analysis. Clin Psychol Psychother 1998;5:126-144.
  52. Hidalgo RB, Davidson JR. Selective serotonin reuptake inhibitors in post-traumatic stress disorder. J Psychopharmacol 2000;14:70-76.
    Pubmed
  53. Seedat S, Warwick J, van Heerden B, Hugo C, Zungu-Dirwayi N, Van Kradenburg J, Stein DJ. Single photon emission computed tomography in posttraumatic stress disorder before and after treatment with a selective serotonin reuptake inhibitor. J Affect Disord 2004;80:45-53.
    Pubmed
  54. Peres JF, Newberg AB, Mercante JP, Simão M, Albuquerque VE, Peres MJ, Nasello AG. Cerebral blood flow changes during retrieval of traumatic memories before and after psychotherapy: a SPECT study. Psychol Med 2007;37:1481-1491.
    Pubmed
  55. Lindauer RJ, Booij J, Habraken JB, van Meijel EP, Uylings HB, Olff M, Carlier IV, den Heeten GJ, van Eck-Smit BL, Gersons BP. Effects of psychotherapy on regional cerebral blood flow during trauma imagery in patients with post-traumatic stress disorder: a randomized clinical trial. Psychol Med 2008;38:543-554.
    Pubmed
  56. Levin P, Lazrove S, van der Kolk B. What psychological testing and neuroimaging tell us about the treatment of posttraumatic stress disorder by eye movement desensitization and reprocessing. J Anxiety Disord 1999;13:159-172.
    Pubmed
  57. Lansing K, Amen DG, Hanks C, Rudy L. High-resolution brain SPECT imaging and eye movement desensitization and reprocessing in police officers with PTSD. J Neuropsychiatry Clin Neurosci 2005;17:526-532.
    Pubmed
  58. Pagani M, Högberg G, Salmaso D, Nardo D, Sundin O, Jonsson C, Soares J, Aberg-Wistedt A, Jacobsson H, Larsson SA, Hällström T. Effects of EMDR psychotherapy on 99mTc-HMPAO distribution in occupation-related post-traumatic stress disorder. Nucl Med Commun 2007;28:757-765.
    Pubmed
  59. Bremner JD, Innis RB, Southwick SM, Staib L, Zoghbi S, Charney DS. Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder. Am J Psychiatry 2000;157:1120-1126.
    Pubmed
  60. Fujita M, Southwick SM, Denucci CC, Zoghbi SS, Dillon MS, Baldwin RM, Bozkurt A, Kugaya A, Verhoeff NP, Seibyl JP, Innis RB. Central type benzodiazepine receptors in Gulf War veterans with posttraumatic stress disorder. Biol Psychiatry 2004;56:95-100.
    Pubmed
  61. Hoexter MQ, Fadel G, Felício AC, Calzavara MB, Batista IR, Reis MA, Shih MC, Pitman RK, Andreoli SB, Mello MF, Mari JJ, Bressan RA. Higher striatal dopamine transporter density in PTSD: an in vivo SPECT study with [(99m)Tc] TRODAT-1. Psychopharmacology (Berl) 2012;224:337-345.
    Pubmed
  62. Weizman R, Weizman A, Kook KA, Vocci F, Deutsch SI, Paul SM. Repeated swim stress alters brain benzodiazepine receptors measured in vivo. J Pharmacol Exp Ther 1989;249:701-707.
    Pubmed
  63. Yehuda R, Southwick S, Giller EL, Ma X, Mason JW. Urinary catecholamine excretion and severity of PTSD symptoms in Vietnam combat veterans. J Nerv Ment Dis 1992;180:321-325.
    Pubmed
  64. Charney DS, Deutch AY, Krystal JH, Southwick SM, Davis M. Psychobiologic mechanisms of posttraumatic stress disorder. Arch Gen Psychiatry 1993;50:295-305.
    Pubmed
  65. Comings DE, Muhleman D, Gysin R. Dopamine D2 receptor (DRD2) gene and susceptibility to posttraumatic stress disorder: a study and replication. Biol Psychiatry 1996;40:368-372.
    Pubmed
  66. De Bellis MD, Baum AS, Birmaher B, Keshavan MS, Eccard CH, Boring AM, Jenkins FJ, Ryan ND. A.E. Bennett Research Award. Developmental traumatology. Part I: Biological stress systems. Biol Psychiatry 1999;45:1259-1270.
    Pubmed
  67. Malhi GS, Valenzuela M, Wen W, Sachdev P. Magnetic resonance spectroscopy and its applications in psychiatry. Aust N Z J Psychiatry 2002;36:31-43.
    Pubmed
  68. Karl A, Werner A. The use of proton magnetic resonance spectroscopy in PTSD research--meta-analyses of findings and methodological review. Neurosci Biobehav Rev 2010;34:7-22.
    Pubmed
  69. Schür RR, Draisma LW, Wijnen JP, Boks MP, Koevoets MG, Joëls M, Klomp DW, Kahn RS, Vinkers CH. Brain GABA levels across psychiatric disorders: a systematic literature review and meta-analysis of 1H-MRS studies. Hum Brain Mapp 2016;37:3337-3352.
    Pubmed
  70. Shin LM, Whalen PJ, Pitman RK, Bush G, Macklin ML, Lasko NB, Orr SP, McInerney SC, Rauch SL. An fMRI study of anterior cingulate function in posttraumatic stress disorder. Biol Psychiatry 2001;50:932-942.
    Pubmed
  71. Carrión VG, Haas BW, Garrett A, Song S, Reiss AL. Reduced hippocampal activity in youth with posttraumatic stress symptoms: an FMRI study. J Pediatr Psychol 2010;35:559-569.
    Pubmed
  72. Pitman RK, Rasmusson AM, Koenen KC, Shin LM, Orr SP, Gilbertson MW, Milad MR, Liberzon I. Biological studies of post-traumatic stress disorder. Nat Rev Neurosci 2012;13:769-787.
    Pubmed
  73. Sekiguchi A, Sugiura M, Taki Y, Kotozaki Y, Nouchi R, Takeuchi H, Araki T, Hanawa S, Nakagawa S, Miyauchi CM, Sakuma A, Kawashima R. Brain structural changes as vulnerability factors and acquired signs of post-earthquake stress. Mol Psychiatry 2013;18:618-623.
    Pubmed
  74. Sekiguchi A, Kotozaki Y, Sugiura M, Nouchi R, Takeuchi H, Hanawa S, Nakagawa S, Miyauchi CM, Araki T, Sakuma A, Taki Y, Kawashima R. Resilience after 3/11: structural brain changes 1 year after the Japanese earthquake. Mol Psychiatry 2015;20:553-554.
    Pubmed
  75. De Bellis MD, Keshavan MS, Spencer S, Hall J. N-Acetylaspartate concentration in the anterior cingulate of maltreated children and adolescents with PTSD. Am J Psychiatry 2000;157:1175-1177.
    Pubmed
  76. Freeman TW, Cardwell D, Karson CN, Komoroski RA. In vivo proton magnetic resonance spectroscopy of the medial temporal lobes of subjects with combat-related posttraumatic stress disorder. Magn Reson Med 1998;40:66-71.
    Pubmed
  77. Hammen T, Stefan H, Eberhardt KE, W-Huk BH, Tomandl BF. Clinical applications of 1H-MR spectroscopy in the evaluation of epilepsies--what do pathological spectra stand for with regard to current results and what answers do they give to common clinical questions concerning the treatment of epilepsies?. Acta Neurol Scand 2003;108:223-238.
    Pubmed
  78. Tamiya T, Kinoshita K, Ono Y, Matsumoto K, Furuta T, Ohmoto T. Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiology 2000;42:333-338.
    Pubmed
  79. Glodzik-Sobanska L, Slowik A, Kieltyka A, Kozub J, Sobiecka B, Urbanik A, Szczudlik A. Reduced prefrontal N-acetylaspartate in stroke patients with apathy. J Neurol Sci 2005;238:19-24.
    Pubmed
  80. Glodzik-Sobanska L, Li J, Mosconi L, Slowik A, Walecki J, Szczudlik A, Sobiecka B, de Leon MJ. Prefrontal N-acetylaspartate and poststroke recovery: a longitudinal proton spectroscopy study. AJNR Am J Neuroradiol 2007;28:470-474.
    Pubmed
  81. Gruber S, Frey R, Mlynárik V, Stadlbauer A, Heiden A, Kasper S, Kemp GJ, Moser E. Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla. Invest Radiol 2003;38:403-408.
    Pubmed
  82. Szulc A, Galińska B, Tarasów E, Kubas B, Dzienis W, Konarzewska B, Poplawska R, Tomczak AA, Czernikiewicz A, Walecki J. N-acetylaspartate (NAA) levels in selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics: a proton magnetic resonance spectroscopy (1H MRS) study. Med Sci Monit 2007;13:17-22.
    Pubmed
  83. Maddock RJ, Buonocore MH. In: Carter CS, Dalley JW. Brain imaging in behavioral neuroscience. Heidelberg: Springer, 2012; 2012. p. 199-251.
  84. Schuff N, Neylan TC, Lenoci MA, Du AT, Weiss DS, Marmar CR, Weiner MW. Decreased hippocampal N-acetylaspartate in the absence of atrophy in posttraumatic stress disorder. Biol Psychiatry 2001;50:952-959.
    Pubmed
  85. Villarreal G, Petropoulos H, Hamilton DA, Rowland LM, Horan WP, Griego JA, Moreshead M, Hart BL, Brooks WM. Proton magnetic resonance spectroscopy of the hippocampus and occipital white matter in PTSD: preliminary results. Can J Psychiatry 2002;47:666-670.
    Pubmed
  86. Ham BJ, Chey J, Yoon SJ, Sung Y, Jeong DU, Ju Kim S, Sim ME, Choi N, Choi IG, Renshaw PF, Lyoo IK. Decreased N-acetyl-aspartate levels in anterior cingulate and hippocampus in subjects with post-traumatic stress disorder: a p roton m agnetic resonance spectroscopy study. Eur J Neurosci 2007;25:324-329.
    Pubmed
  87. Yang B, Zhou YC, Xia J, Xia LM, Wang CY. The study of the volume and 1H MRS of the hippocampus in posttraumatic stress disorder. Zhonghua Fang She Xue Za Zhi 2006;40:36-40.
  88. Mohanakrishnan Menon P, Nasrallah HA, Lyons JA, Scott MF, Liberto V. Single-voxel proton MR spectroscopy of right versus left hippocampi in PTSD. Psychiatry Res 2003;123:101-108.
    Pubmed
  89. Mahmutyazicioğlu K, Konuk N, Özdemir H, Atasoy N, Atik L, Gündoğdu S. Evaluation of the hippocampus and the anterior cingulate gyrus by proton MR spectroscopy in patients with post-traumatic stress disorder. Diagn Interv Radiol 2005;11:125-129.
    Pubmed
  90. Li L, Chen S, Liu J, Zhang J, He Z, Lin X. Magnetic resonance imaging and magnetic resonance spectroscopy study of deficits in hippocampal structure in fire victims with recent-onset posttraumatic stress disorder. Can J Psychiatry 2006;51:431-437.
    Pubmed
  91. Guo M, Chen F, Guo JC, Lu CZ, Jiang XL, Liu T, Li M, Song W. Study of the hippocampus and the anterior cingulate gyrus by proton MR spectroscopy in patients with post-traumatic stress disorder. Asian Pac J Trop Med 2012;5:162-164.
    Pubmed
  92. Shu XJ, Xue L, Liu W, Chen FY, Zhu C, Sun XH, Wang XP, Liu ZC, Zhao H. More vulnerability of left than right hippocampal damage in right-handed patients with post-traumatic stress disorder. Psychiatry Res 2013;212:237-244.
    Pubmed
  93. Brown S, Freeman T, Kimbrell T, Cardwell D, Komoroski R. In vivo proton magnetic resonance spectroscopy of the medial temporal lobes of former prisoners of war with and without posttraumatic stress disorder. J Neuropsychiatry Clin Neurosci 2003;15:367-370.
    Pubmed
  94. Freeman T, Kimbrell T, Booe L, Myers M, Cardwell D, Lindquist DM, Hart J, Komoroski RA. Evidence of resilience: neuroimaging in former prisoners of war. Psychiatry Res 2006;146:59-64.
    Pubmed
  95. Seedat S, Videen JS, Kennedy CM, Stein MB. Single voxel proton magnetic resonance spectroscopy in women with and without intimate partner violence-related posttraumatic stress disorder. Psychiatry Res 2005;139:249-258.
    Pubmed
  96. Meyerhoff DJ, Mon A, Metzler T, Neylan TC. Cortical gamma-aminobutyric acid and glutamate in posttraumatic stress disorder and their relationships to self-reported sleep quality. Sleep 2014;37:893-900.
    Pubmed
  97. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003;70:83-244.
    Pubmed
  98. Wijtenburg SA, Yang S, Fischer BA, Rowland LM. In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophrenia. Neurosci Biobehav Rev 2015;51:276-295.
    Pubmed
  99. Mullins PG, McGonigle DJ, O’Gorman RL, Puts NA, Vidyasagar R, Evans CJ, Edden RA, Cardiff Symposium on MRS of GABA. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. Neuroimage 2014;86:43-52.
    Pubmed
  100. Andreychenko A, Boer VO, Arteaga de Castro CS, Luijten PR, Klomp DW. Efficient spectral editing at 7 T: GABA detection with MEGA-sLASER. Magn Reson Med 2012;68:1018-1025.
    Pubmed
  101. Michels L, Schulte-Vels T, Schick M, O’Gorman RL, Zeffiro T, Hasler G, Mueller-Pfeiffer C. Prefrontal GABA and glutathione imbalance in posttraumatic stress disorder: preliminary findings. Psychiatry Res 2014;224:288-295.
    Pubmed
  102. Rosso IM, Weiner MR, Crowley DJ, Silveri MM, Rauch SL, Jensen JE. Insula and anterior cingulate GABA levels in posttraumatic stress disorder: preliminary findings using magnetic resonance spectroscopy. Depress Anxiety 2014;31:115-123.
    Pubmed
  103. Yang ZY, Quan H, Peng ZL, Zhong Y, Tan ZJ, Gong QY. Proton magnetic resonance spectroscopy revealed differences in the glutamate + glutamine/creatine ratio of the anterior cingulate cortex between healthy and pediatric post-traumatic stress disorder patients diagnosed after 2008 Wenchuan earthquake. Psychiatry Clin Neurosci 2015;69:782-790.
    Pubmed